气候变化领域集成服务门户(CCPortal): Estrogen receptor β and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate

CCPortal

DOI	10.1073/PNAS.2011269118
	Estrogen receptor β and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate
	Wu W.-F.; Wang L.; Spetsieris N.; Boukovala M.; Efstathiou E.; Brössner C.; Warner M.; Gustafsson J.-A.
发表日期	2021
ISSN	00278424
卷号	118 期号:13
英文摘要	Knockout of ERβ in the mouse leads to nuclear expression of epidermal growth factor receptor (EGFR) in the prostate. To examine whether ERβ plays a similar role in the human prostate, we used four cohorts of men: 1) a Swedish cohort of normal prostates and PCa (prostate cancer) of different Gleason grades; 2) men with benign prostatic hyperplasia (BPH) treated with the 5α-reductase inhibitor, finasteride, and finasteride together with the ERβ agonists, soy isoflavones; 3) men with PCa above Gleason grade 4 (GG4), treated with ADT (androgen deprivation therapy) and abiraterone (AA), the blocker of androgen synthesis for different durations; and 4) men with GG4 PCa on ADT or ADT with the AR (androgen receptor) blocker, enzalutamide, for 4 mo to 6 mo. In men with BPH, finasteride treatment induced EGFR nuclear expression, but, when finasteride was combined with isoflavones, EGFR remained on the cell membrane. In GG4 patients, blocking of AR for 4 mo to 6 mo resulted in loss of ERβ and PTEN expression and increase in patients with nuclear EGFR from 10 to 40%. In the men with GG4 PCa, blocking of adrenal synthesis of testosterone for 2 mo to 7 mo had the beneficial effect of increasing ERβ expression, but, on treatment longer than 8 mo, ERβ was lost and EGFR moved to the nucleus. Since nuclear EGFR is a predictor of poor outcome in PCa, addition of ERβ agonists together with abiraterone should be considered as a treatment that might sustain expression of ERβ and offer some benefit to patients. © 2021 National Academy of Sciences. All rights reserved.
英文关键词	ADT; EGFR; Nuclear receptor; Prostate cancer; PTEN
语种	英语
scopus关键词	abiraterone; androgen receptor; enzalutamide; epidermal growth factor receptor; estrogen receptor beta; finasteride; isoflavone derivative; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; phytoestrogen; testosterone; adult; aged; androgen deprivation therapy; animal cell; Article; cancer recurrence; clinical article; clinical outcome; cohort analysis; controlled study; drug effect; Gleason score; human; human cell; human tissue; immunohistochemistry; male; mouse; multiple cycle treatment; nonhuman; nucleocytoplasmic transport; predictor variable; priority journal; prostate; prostate cancer; prostate hypertrophy; protein depletion; protein expression; protein function; Swedish citizen; testosterone synthesis
来源期刊	Proceedings of the National Academy of Sciences of the United States of America
文献类型	期刊论文
条目标识符	http://gcip.llas.ac.cn/handle/2XKMVOVA/180044
作者单位	Center for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, TX 77204, United States; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States; Department of Urology, Barmherzige Schwestern Hospital, Vienna, 1060, Austria; Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, 14157, Sweden
推荐引用方式 GB/T 7714	Wu W.-F.,Wang L.,Spetsieris N.,et al. Estrogen receptor β and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate[J],2021,118(13).
APA	Wu W.-F..,Wang L..,Spetsieris N..,Boukovala M..,Efstathiou E..,...&Gustafsson J.-A..(2021).Estrogen receptor β and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate.Proceedings of the National Academy of Sciences of the United States of America,118(13).
MLA	Wu W.-F.,et al."Estrogen receptor β and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate".Proceedings of the National Academy of Sciences of the United States of America 118.13(2021).